Hologic, Inc.’s Stock Price Underperforms at $60.56, Slides Down by 1.34%

Hologic, Inc. (HOLX)

60.56 USD -0.82 (-1.34%) Volume: 1.34M

Hologic, Inc.’s stock price currently stands at 60.56 USD, experiencing a slight dip of -1.34% in the latest trading session with a trading volume of 1.34M. Despite this short-term fluctuation, the year-to-date performance shows a significant decrease of -15.99%, reflecting the overall downward trend in HOLX’s stock price.

Latest developments on Hologic, Inc.

Hologic Inc. (HOLX) has been making waves in the stock market recently, with Evercore ISI adjusting its price target on the company to $65 from $73 while maintaining an In Line rating. Additionally, Mitsubishi UFJ Trust & Banking Corp holds a significant $13.99 million stock position in Hologic, Inc. (NASDAQ:HOLX). Despite declining stock prices, Hologic has shown decent financials, leading to questions about whether the market may be underestimating its potential. As Hologic (HOLX) continues to outperform the broader market, investors are keeping a close eye on the company for future business opportunities in the Bone Densitometers Market.

Hologic, Inc. on Smartkarma

Analysts at Baptista Research have been closely monitoring Hologic Inc, a company specializing in 3D mammography and molecular diagnostics. In their report titled “Hologic: The Future of 3D Mammography and Molecular Diagnostics—What’s Next?”, they highlighted the company’s first-quarter fiscal 2025 results. Despite facing some challenges impacting revenue streams, Hologic reported a modest 1% increase in overall revenue, reaching $1.022 billion. The analysts noted the impact of the stronger U.S. dollar, which slightly reduced reported revenue by about $9 million.

Furthermore, Baptista Research published another report on Hologic Inc titled “Hologic Inc.: Expanding Diagnostic Assay Portfolio For A Competitive Edge! – Major Drivers”. This report focused on the company’s financial results for the fourth quarter and fiscal year 2024. Hologic reported a total revenue of $987.9 million in the fourth quarter, showing a 4.2% increase compared to the previous year. Organic revenue growth, excluding COVID-related sales, was at 5%. Additionally, non GAAP earnings per share (EPS) grew by 13.5% to $1.01, indicating both strengths and challenges for the company.

A look at Hologic, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Hologic Inc has a mixed long-term outlook. While the company receives a high score for momentum, indicating strong market performance, its scores for value, growth, resilience, and dividend are relatively lower. This suggests that while Hologic Inc may be performing well in the short term, there may be challenges in terms of long-term growth and stability.

Hologic, Inc. is a developer, manufacturer, and supplier of premium diagnostic products, medical imaging systems, and surgical products. The company’s core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a mixed outlook based on the Smartkarma Smart Scores, investors may want to carefully consider the various factors at play before making decisions regarding Hologic Inc‘s future performance.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

Before it’s here, it’s on Smartkarma